KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $0.87 $1.65 Friday, 26th Apr 2024 ADAP stock ended at $1.08. This is 1.42% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 5.83% from a day low at $1.03 to a day high of $1.09.
90 days $0.730 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
Dec 01, 2022 $2.15 $2.18 $2.01 $2.02 224 002
Nov 30, 2022 $2.25 $2.38 $2.15 $2.17 356 751
Nov 29, 2022 $2.15 $2.28 $2.10 $2.19 469 632
Nov 28, 2022 $2.20 $2.30 $2.09 $2.11 284 185
Nov 25, 2022 $2.26 $2.40 $2.19 $2.20 152 004
Nov 23, 2022 $2.41 $2.52 $2.18 $2.23 426 244
Nov 22, 2022 $2.54 $2.54 $2.30 $2.44 588 941
Nov 21, 2022 $2.31 $2.54 $2.30 $2.51 373 311
Nov 18, 2022 $2.42 $2.43 $2.32 $2.37 302 237
Nov 17, 2022 $2.21 $2.37 $2.20 $2.35 276 107
Nov 16, 2022 $2.37 $2.38 $2.24 $2.35 669 278
Nov 15, 2022 $2.51 $2.61 $2.32 $2.46 533 786
Nov 14, 2022 $2.52 $2.64 $2.43 $2.63 1 038 435
Nov 11, 2022 $2.30 $2.57 $2.28 $2.50 819 841
Nov 10, 2022 $2.10 $2.25 $2.03 $2.25 599 945
Nov 09, 2022 $2.20 $2.27 $2.04 $2.11 1 356 912
Nov 08, 2022 $1.78 $2.15 $1.70 $2.08 1 457 606
Nov 07, 2022 $1.63 $1.71 $1.57 $1.66 294 142
Nov 04, 2022 $1.62 $1.64 $1.56 $1.60 391 361
Nov 03, 2022 $1.50 $1.63 $1.46 $1.59 255 321
Nov 02, 2022 $1.47 $1.53 $1.41 $1.51 197 241
Nov 01, 2022 $1.44 $1.50 $1.41 $1.45 355 199
Oct 31, 2022 $1.38 $1.45 $1.38 $1.42 187 763
Oct 28, 2022 $1.34 $1.41 $1.33 $1.39 224 158
Oct 27, 2022 $1.36 $1.40 $1.30 $1.37 256 275
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT